Harmony Biosciences
HRMY
311 hedge funds and large institutions have $1.57B invested in Harmony Biosciences in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 132 increasing their positions, 97 reducing their positions, and 51 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 97
9.82% more ownership
Funds ownership: 86.97% → 96.79% (+9.8%)
4% less funds holding
Funds holding: 325 → 311 (-14)
14% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 51
16% less capital invested
Capital invested by funds: $1.87B → $1.57B (-$305M)
38% less call options, than puts
Call options by funds: $12.4M | Put options by funds: $20.1M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$36.9M |
| 2 |
SG Americas Securities
New York
|
+$34.6M |
| 3 |
Millennium Management
New York
|
+$23.7M |
| 4 |
Goldman Sachs
New York
|
+$22M |
| 5 |
JP Morgan Chase
New York
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$21.8M |
| 2 |
6CM
683 Capital Management
New York
|
-$13.6M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$10.9M |
| 4 |
Janus Henderson Group
London,
|
-$10M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$8.89M |
HRMY Hedge Fund Activity: Q1 2026 in Review
311 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2026, worth a combined $1.57B — down 16% from $1.87B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of HRMY and 44 opened new positions — a net loss of 7 holders — while 97 trimmed existing stakes and 132 added.
The largest buyer was Armistice Capital, adding an estimated $36.9M. The largest seller was Boston Partners, cutting an estimated $21.8M.
- 311 institutional investors held Harmony Biosciences (HRMY) as of Q1 2026, down from 325 in Q4 2025.
- Funds reported $1.57B of Harmony Biosciences stock for Q1 2026, down 16% quarter-over-quarter.
- 44 funds opened new Harmony Biosciences positions in Q1 2026 and 51 closed out, a net change of -7 holders.
- The largest Harmony Biosciences buyer in Q1 2026 was Armistice Capital, an estimated $36.9M added.
- The largest Harmony Biosciences seller in Q1 2026 was Boston Partners, an estimated $21.8M sold.
Based on aggregated 13F filings for Q1 2026.